Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | SMO | Q99835 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290340 | 0.90 | EPHX2 (0.58) | EPHX2TLR2TSHRFAAHKMT2A | |
| SCHEMBL16289859 | 0.90 | EPHX2 (0.58) | EPHX2TLR2TSHRFAAHKMT2A | |
| SCHEMBL19197510 | 0.87 | TSHR (0.64) | CA1CA2EPHX2TSHRKMT2A | |
| SCHEMBL5399655 | 0.86 | CA1 (0.52) | CA1CA2EPHX2HDAC8HDAC3 | |
| SCHEMBL22294656 | 0.84 | LMNA (0.58) | EPHX2TLR2CNR2TSHRFAAH | |
| SCHEMBL12352667 | 0.84 | LMNA (0.58) | EPHX2TLR2CNR2TSHRFAAH | |
| SCHEMBL17531100 | 0.82 | SPHK1 (0.64) | EPHX2TLR2CNR2FAAHKMT2A | |
| SCHEMBL13933114 | 0.82 | CA1 (0.45) | CA1CA2EPHX2SMO | |
| SCHEMBL6843706 | 0.81 | MMP8 (0.59) | CA1CA2HDAC8HDAC3HDAC1 | |
| SCHEMBL10939549 | 0.80 | EPHX2 (0.54) | EPHX2TLR2CNR2FAAHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CA1 3863/4885CA2 1311/4885EPHX2 2412/4885 |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | CA1 3863/4885CA2 1311/4885EPHX2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.